title: Fulminant course of osteonecrosis of the jaw in a rheumatoid arthritis patient following oral bisphosphonate intake and biologic therapy.
authors.forename: Tobias
authors.initials: T
authors.lastname: Ebker
authors.forename: Juergen
authors.initials: J
authors.lastname: Rech
authors.forename: Cornelius
authors.initials: C
authors.lastname: von Wilmowsky
authors.forename: Friedrich Wilhelm
authors.initials: FW
authors.lastname: Neukam
authors.forename: Philipp
authors.initials: P
authors.lastname: Stockmann
mesh_terms: D000328:Adult; D000368:Aged; D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use; D018501:Antirheumatic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D059266:Bisphosphonate-Associated Osteonecrosis of the Jaw / Q000175:diagnosis* / Q000209:etiology; D004164:Diphosphonates / Q000009:adverse effects* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D000069285:Infliximab; D010024:Osteoporosis / Q000188:drug therapy*
chemical_list: D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D004164:Diphosphonates; D000069285:Infliximab